Myokardia Inc (OQ:MYOK)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 1000 Sierra Point Parkway
Tel: 1-650-3514690
IR: See website
Key People
Tassos Anastasios Gianakakos
President, Chief Executive Officer, Director
Taylor C. Harris
Chief Financial Officer
William C. Fairey
Executive Vice President and Chief Commercial Officer
Robert Scott McDowell
Chief Scientific Officer
Denelle Waynick
General Counsel, Corporate Secretary
Jake Bauer
Chief Business Officer
Business Overview
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
Financial Overview
For the three months ended 31 March 2020, Myokardia Inc revenues was not reported. Net loss increased 86% to $69.9M. Higher net loss reflects Research and development - Balancing increase from $23.2M to $46.7M (expense), General and administrative - Balancing increase of 50% to $14.3M (expense), Stock-based Compensation in R&D increase of 75% to $5.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.93 to -$1.50.
Employees: 246 as of Mar 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $4,553M as of Mar 31, 2020
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$317.59M as of Mar 31, 2020
Net annual income (TTM): -$308.61M as of Mar 31, 2020
Free cash flow (TTM): -$278.70M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 52,649,686 as of May 12, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization